New national study into the long-term health impacts of COVID-19 launched

New national study into the long-term health impacts of COVID-19 launched

A major UK research study into the long-term health impacts of COVID-19 on hospitalised patients has been launched today involving researchers from the University of Aberdeen.

The PHOSP-COVID study has been awarded £8.4million jointly by UK Research and Innovation (UKRI) and the National Institute for Health Research (NIHR). This study is one of a number of COVID-19 studies that have been given urgent public health research status by the UK government Department of Health and Social Care.

Led by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre (a partnership between  the University of Leicester and the University Hospitals of Leicester NHS Trust), the PHOSP-COVID study  will draw on expertise from a consortium of leading researchers and clinicians from across the UK to assess the impact of COVID-19 on patient health and their recovery.

 

Around 10,000 patients are expected to take part, making it the largest comprehensive study in the world to understand and improve the health of survivors after hospitalisation from COVID-19.

Health and Social Care Secretary Matt Hancock said:“As we continue our fight against this global pandemic, we are learning more and more about the impact the disease can have not only on immediate health, but longer-term physical and mental health too.

“This world-leading study is another fantastic contribution from the UK's world-leading life sciences and research sector. It will also help to ensure future treatment can be tailored as much as possible to the person.”

Chief Medical Officer Professor Chris Whitty said: “As well as the immediate health impacts of the virus it is also important to look at the longer term impacts on health, which may be significant.

“We have rightly focused on mortality, and what the UK can do straight away to protect lives but we should also look at how COVID-19 impacts on the health of people after they have recovered from the immediate disease.

“This UKRI and NIHR funded study is one of the first steps in doing this.”

Chris Brightling, Professor of Respiratory Medicine at the University of Leicester, Consultant Respiratory Physician at University Hospitals of Leicester NHS Trust, and chief investigator for the study said:“As we emerge from the first wave of the pandemic, we have new insights into the acute phase of this disease but very little information about patients’ long term needs.

“It is vitally important that we rapidly gather evidence on the longer term consequences of contracting severe COVID-19 so we can develop and test new treatment strategies for them and other people affected by future waves of the disease.”

Professor Dana Dawson, Chair in Cardiovascular Medicine at the University of Aberdeen said: “At the University of Aberdeen, we are delighted to bring our expertise to this essential research, where we will unravel the consequent health burden in the aftermath of the covid-19 pandemic.

“Fuelled by inter-disciplinary collaboration in all fields of medicine, this work will reveal the knowledge we need in order to provide the best patient care for all those who suffered from this devastating disease.”

Symptoms of COVID-19 have varied among those who have tested positive: some have displayed no symptoms, while others have developed severe pneumonia and sadly even lost their lives. For those who were hospitalised and have since been discharged, it is not yet clear what the medical, psychological and rehabilitation needs for this group of patients will be to enable them to make as full a recovery as possible.

Patients on the study will be assessed using techniques such as advanced imaging, data collection and analysis of blood and lung samples, creating a comprehensive picture of the impact COVID-19 has had on longer term health outcomes across the UK.

The PHOSP-COVID team will then develop trials of new strategies for clinical care, including personalised treatments for groups of patients based on the particular disease characteristics they show as a result of having COVID-19 to improve their long term health.

The PHOSP-COVID study is widely supported across the NIHR infrastructure, including the Translational Research Collaborations for respiratory, mental health, cardiovascular, dementia, and diet, exercise and nutrition, and many of the NIHR Biomedical Research Centres, which are set up to translate lab-based scientific breakthroughs into potential new treatments, diagnostics and medical technologies.

To follow the study as it develops, visit www.phosp.org.

Search News

Browse by Month

2020

  1. Jan
  2. Feb
  3. Mar
  4. Apr
  5. May
  6. Jun
  7. Jul
  8. Aug There are no items to show for August 2020
  9. Sep There are no items to show for September 2020
  10. Oct There are no items to show for October 2020
  11. Nov There are no items to show for November 2020
  12. Dec There are no items to show for December 2020

2019

  1. Jan
  2. Feb There are no items to show for February 2019
  3. Mar
  4. Apr
  5. May
  6. Jun
  7. Jul
  8. Aug
  9. Sep
  10. Oct
  11. Nov
  12. Dec

2018

  1. Jan There are no items to show for January 2018
  2. Feb There are no items to show for February 2018
  3. Mar There are no items to show for March 2018
  4. Apr There are no items to show for April 2018
  5. May There are no items to show for May 2018
  6. Jun There are no items to show for June 2018
  7. Jul There are no items to show for July 2018
  8. Aug There are no items to show for August 2018
  9. Sep
  10. Oct
  11. Nov
  12. Dec